OTCQB
ACHFF

Arch Biopartners Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Arch Biopartners Inc Stock Price

Vitals

Today's Low:
$1.1
Today's High:
$1.16
Open Price:
$1.13
52W Low:
$1.56
52W High:
$3.38
Prev. Close:
$1.133
Volume:
51100

Company Statistics

Market Cap.:
$108.80 million
Book Value:
-0.072
Revenue TTM:
$964497
Operating Margin TTM:
-314.91%
Gross Profit TTM:
$-502879
Profit Margin:
0%
Return on Assets TTM:
-170.05%
Return on Equity TTM:
0%

Company Profile

Arch Biopartners Inc had its IPO on under the ticker symbol ACHFF.

The company operates in the Healthcare sector and Biotechnology industry. Arch Biopartners Inc has a staff strength of 0 employees.

Stock update

Shares of Arch Biopartners Inc opened at $1.13 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.1 - $1.16, and closed at $1.13.

This is a -0.26% slip from the previous day's closing price.

A total volume of 51,100 shares were traded at the close of the day’s session.

In the last one week, shares of Arch Biopartners Inc have slipped by -7.76%.

Arch Biopartners Inc's Key Ratios

Arch Biopartners Inc has a market cap of $108.80 million, indicating a price to book ratio of 0 and a price to sales ratio of 38.1898.

In the last 12-months Arch Biopartners Inc’s revenue was $964497 with a gross profit of $-502879 and an EBITDA of $0. The EBITDA ratio measures Arch Biopartners Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Arch Biopartners Inc’s operating margin was -314.91% while its return on assets stood at -170.05% with a return of equity of 0%.

In Q4, Arch Biopartners Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Arch Biopartners Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.02 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Arch Biopartners Inc’s profitability.

Arch Biopartners Inc stock is trading at a EV to sales ratio of 40.3681 and a EV to EBITDA ratio of 5435.676. Its price to sales ratio in the trailing 12-months stood at 38.1898.

Arch Biopartners Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$718124.00
Total Liabilities
$2.90 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Arch Biopartners Inc ended 2024 with $718124.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $718124.00 while shareholder equity stood at $-4468892.00.

Arch Biopartners Inc ended 2024 with $0 in deferred long-term liabilities, $2.90 million in other current liabilities, in common stock, $-26882020.00 in retained earnings and $0 in goodwill. Its cash balance stood at $159818.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $2.29 million.

Arch Biopartners Inc’s total current assets stands at $718124.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $434719.00 compared to accounts payable of $768119.00 and inventory worth $0.

In 2024, Arch Biopartners Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Arch Biopartners Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.13
52-Week High
$3.38
52-Week Low
$1.56
Analyst Target Price
$

Arch Biopartners Inc stock is currently trading at $1.13 per share. It touched a 52-week high of $3.38 and a 52-week low of $3.38. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $1.43 and 200-day moving average was $1.67 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 1918.6% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Arch Biopartners Inc

The stock symbol (also called stock or share ticker) of Arch Biopartners Inc is ACHFF

The IPO of Arch Biopartners Inc took place on

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$22.4
0.06
+0.27%
$2.68
-0.14
-4.96%
$493.85
-23.3
-4.51%
$3792
-143
-3.63%
$591.35
-17.5
-2.87%
$34.67
0.1
+0.29%
$0.66
-0.01
-1.33%
$34.54
0.34
+0.99%
$3.44
-0.08
-2.27%
$1346.55
-2.8
-0.21%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Arch Biopartners Inc., a biotechnology company, engages in the development of technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is based in Toronto, Canada.

Address

27 Street Clair Avenue East, Toronto, ON, Canada, M4T 2M5